Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Core Insights - Lexicon Pharmaceuticals presented a post-hoc analysis showing that treatment with sotagliflozin, when added to optimized insulin therapy, resulted in a reduction of hypoglycemic events in patients with type 1 diabetes (T1D) without increasing risk [1][5][6] Group 1: Clinical Findings - The analysis indicated that sotagliflozin significantly reduced hypoglycemic events, particularly in patients with blood glucose levels ≤55 mg/dL [1][5] - Chronic kidney disease (CKD) is a notable risk factor for hypoglycemia in T1D, with 20% to 40% of T1D patients developing CKD [3] - The study evaluated the effect of kidney function on hypoglycemia risk using data from two Phase 3 clinical trials, inTandem 1 and inTandem 2, which compared sotagliflozin to placebo [4][5] Group 2: Treatment Efficacy - Results showed that sotagliflozin maintained a consistent trend of reduced hypoglycemia across different estimated glomerular filtration rate (eGFR) subgroups [5] - The treatment led to lower rates of severe hypoglycemia compared to placebo, reinforcing its potential as a safer adjunct therapy for T1D patients [5][6] Group 3: Company Overview - Lexicon Pharmaceuticals focuses on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to discover therapeutic targets [7] - The company has a diverse pipeline of drug candidates in various stages of development, addressing conditions such as neuropathic pain, hypertrophic cardiomyopathy, and obesity [7]